# A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

> **NCT05326516** · PHASE1 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Relapsed/Refractory Leukemias
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- Mixed Phenotype Acute Leukemia
- Acute Myeloid Leukemia
- Acute Undifferentiated Leukemia

## Interventions

- **DRUG:** Revumenib
- **DRUG:** Chemotherapy Regimen 1
- **DRUG:** Chemotherapy Regimen 2

## Key facts

- **NCT ID:** NCT05326516
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-09
- **Primary completion:** 2024-07-29
- **Final completion:** 2024-07-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05326516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05326516, "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05326516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*